We are one of the few biotechnology companies globally adopting a systematic therapeutic approach to harness both the innate and adaptive immune systems, unleashing their synergistic potential to address the limitations of T-cell-based immunotherapies. Currently approved immuno-oncology therapies promote immune responses primarily through approaches that target T-cell immune checkpoints, exemplified by PD-1/PD-L1, CTLA-4 and LAG3.